Community-based parenteral anti-infective therapy (CoPAT). Pharmacokinetic and monitoring issues
- PMID: 9673835
- DOI: 10.2165/00003088-199835010-00005
Community-based parenteral anti-infective therapy (CoPAT). Pharmacokinetic and monitoring issues
Abstract
Community-based parenteral anti-infective therapy (CoPAT) has, over the past 20 years, increased rapidly in many parts of the world including North America, Europe, South America and Australia. CoPAT is a multidisciplinary activity demanding close cooperation between nurses, pharmacists and physicians, as well as with the patient. The selection of an anti-infective drug for use outside the hospital setting must take into account not only the therapeutic effectiveness, cost effectiveness and safety of the drug, but also pharmacological factors such as the dosage schedule and the stability of the drug. Dosage schedules vary with pharmacokinetic factors (e.g. the use of drugs with long half-lives are favoured by CoPAT programmes) and pharmacodynamic features (e.g. once daily gentamicin therapy is attractive and practical because of concentration-dependent bactericidal killing and prolonged post-antibiotic effect). With selected drugs, the renal and, to a lesser degree, liver function of the patient will influence the dosage schedule. The mode of intravenous (i.v.) drugs administration will vary with volume considerations (limiting the use of syringe-infusion therapy for some drugs), stability issues (prevents drugs that are stable at room temperature for less than 24 hours from being used in multidose computerised delivery systems), as well as patient factors (ability to self administer an i.v. drug). Monitoring serum anti-microbial concentrations is undertaken to assure effectiveness and avoid toxicity, and is indicated for drugs with a narrow therapeutic window, such as the aminoglycosides. With the advent of the single daily dose administration of aminoglycosides, checking serum concentrations at the mid-point, i.e. 6 to 14 hours following administration of the first dose, is one approach. Because the toxic effects of vancomycin have been overstated, serum concentrations should only be obtained for defined indications primarily to assure therapeutic effectiveness.
Similar articles
-
Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.Clin Pharmacokinet. 2003;42(9):793-817. doi: 10.2165/00003088-200342090-00002. Clin Pharmacokinet. 2003. PMID: 12882587 Review.
-
Comparative pharmacokinetics of teicoplanin and vancomycin.J Chemother. 2000 Nov;12 Suppl 5:15-20. doi: 10.1080/1120009x.2000.11782313. J Chemother. 2000. PMID: 11131959 Review.
-
Practice guidelines for community-based parenteral anti-infective therapy.Infect Dis Clin North Am. 1998 Dec;12(4):1009-21, viii-ix. doi: 10.1016/s0891-5520(05)70034-9. Infect Dis Clin North Am. 1998. PMID: 9888036 Review.
-
Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.Clin Pharmacokinet. 2000 May;38(5):415-26. doi: 10.2165/00003088-200038050-00003. Clin Pharmacokinet. 2000. PMID: 10843460 Review.
-
The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.J Clin Pharm Ther. 2015 Jun;40(3):259-65. doi: 10.1111/jcpt.12270. Epub 2015 Apr 11. J Clin Pharm Ther. 2015. PMID: 25865426 Review.
Cited by
-
Improving antimicrobial treatment in terms of antimicrobial stewardship and health costs by an OPAT service.Infection. 2024 Aug;52(4):1367-1376. doi: 10.1007/s15010-024-02194-0. Epub 2024 Feb 29. Infection. 2024. PMID: 38421503 Free PMC article.
-
Taking the route less traveled: on the way to COpAT.Ther Adv Infect Dis. 2023 Aug 15;10:20499361231192771. doi: 10.1177/20499361231192771. eCollection 2023 Jan-Dec. Ther Adv Infect Dis. 2023. PMID: 37600977 Free PMC article. Review.
-
Comparative pharmacokinetics of the carbapenems: clinical implications.Clin Pharmacokinet. 2000 Sep;39(3):185-201. doi: 10.2165/00003088-200039030-00002. Clin Pharmacokinet. 2000. PMID: 11020134 Review.
-
Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation.Clin Pharmacokinet. 1999 Oct;37(4):289-304. doi: 10.2165/00003088-199937040-00002. Clin Pharmacokinet. 1999. PMID: 10554046 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
